Home

Corcept therapeutics careers

Find out what works well at Corcept Therapeutics from the people who know best. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Compare pay for popular roles and read about the team's work-life balance. Uncover why Corcept Therapeutics is the best company for you 9 Corcept Therapeutics jobs. Apply to the latest jobs near you. Learn about salary, employee reviews, interviews, benefits, and work-life balanc 14 Corcept Therapeutics jobs available in United States on Indeed.com. Apply to Senior Manufacturing Associate, Clinical Research Associate, Medical Director and more Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced the completion of enrollment in its controlled, Phase 2 trial of relacorilant combined with nab.

Corcept Therapeutics Careers and Employment Indeed

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects Learn about working at Corcept Therapeutics. Join LinkedIn today for free. See who you know at Corcept Therapeutics, leverage your professional network, and get hired Search job openings at Corcept Therapeutics. 4 Corcept Therapeutics jobs including salaries, ratings, and reviews, posted by Corcept Therapeutics employees

Corcept Therapeutics jobs 13 open jobs Director jobs 1,022,873 open jobs Associate Director jobs 100,346 open jobs Scientist jobs 47,986 open jobs. Company - Public (CORT) Industry: Biotech & Pharmaceuticals. Revenue: $50 to $100 million (USD) Competitors: UNKNOWN. Corcept Therapeutics wants to help people who are beyond blue. The biotechnology firm is exploring treatments that regulate the presence of Cortisol, a steroid hormone associated with some psychiatric and metabolic disorders Pros. this is from the clinops perspective of the company. giving two stars because outside of clinops, ppl do seem happy and I honestly enjoyed the study I work on. - great pay - there is unlimited PTO - can get rejected/denied by your manager. lots of upper management use of unlimited PTO but i saw multiple lower tier employees be denied PTO. High-Paying Jobs at Corcept Therapeutics. Vice President, Quality Assurance. $250K — $250K+*. Corcept Therapeutics • Menlo Park, CA 94025. 15 days ago. Director, Analytical Development. $250K. 149 Commonwealth Drive Menlo Park, CA 94025. Phone: 650-327-3270 Fax: 650-327-3218 Email: info@corcept.co

A free inside look at Corcept Therapeutics salary trends based on 19 salaries wages for 16 jobs at Corcept Therapeutics. Salaries posted anonymously by Corcept Therapeutics employees Careers at Corcept. We are proud of our corporate culture, which is marked by a sharp focus on the well-being of patients, intellectual rigor, collaboration, and the recognition that the unique. Reviews from Corcept Therapeutics employees about Corcept Therapeutics culture, salaries, benefits, work-life balance, management, job security, and more Today's top 9 Corcept Therapeutics jobs. Leverage your professional network, and get hired. New Corcept Therapeutics jobs added daily

At Corcept, we are committed to discovering and developing safe and effective medical therapies for patients who need them. Support for Patients and Caregivers. We are passionate about educating patients, families, caregivers, and all those impacted by Cushing syndrome Corcept Therapeutics Q1 2019 Earnings Conference Call Apr 24 - Apr 28, 2019 2019 American Association of Clinical Endocrinologists (AACE) 28th Annual Scientific & Clinical Congres Aug 22, 2011 - in Menlo Park, CA. Recommend. CEO Approval. Business Outlook. Pros. The salaries are very competitive, even high compared to other pharmaceutical companies. CEO is warm, communicative and the employees like and respect him. Cons. There is a great deal of secrecy and lack of communication with employees from the president

Corcept Therapeutics To Announce Second Quarter 2021 Financial Results, Provide Corporate Update and Host Conference Call - read this article along with other careers information, tips and advice on BioSpac Corcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial Results. May 6, 2021. Corcept Therapeutics Observes Large Reductions of Liver Fat and Transient Liver Enzyme Elevations in Phase 2 Trial of Miricorilant as a Potential Treatment for Patients with Nonalcoholic Steatohepatitis (NASH) May 6, 2021 Abbott's current market cap-to-operating income ratio of 41x compares with 12x for Emergent Biosolutions, 19x for Vertex Pharmaceuticals, and 22x for Corcept Therapeutics. Does this gap in.

About Corcept Therapeutics. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym ® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing's. Careers at Sorrento Therapeutics, Inc Sorrento Therapeutics, Inc. is an Equal Opportunity Employer and offers candidates an attractive salary and comprehensive benefits package that includes stock options, medical, dental, life and disability insurance, 401k and paid holidays

Corcept Therapeutics Jobs and Careers Indeed

  1. istration for patients with Cushing's.
  2. Founders David Singer. Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Corcept Therapeutics Inc. Stock Symbol NASDAQ:CORT. Company Type For Profit. Contact Email info@corcept.com. Phone Number 16503273218. Since our founding in May 1998 we have been focused on the impact of cortisol and the potential benefits of.
  3. Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Corcept has a large portfolio of proprietary compounds that selectively modulate the effects of cortisol but not.
  4. Proactively sell and promote Corcept Therapeutics products to targeted and non- targeted physicians and healthcare professionals in territory and develop an appropriate territory business plan to.

Corcept Therapeutics is a pharmaceutical company which discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders. Jobs At Similar Companie Glassdoor gives you an inside look at what it's like to work at Corcept Therapeutics, including salaries, reviews, office photos, and more. This is the Corcept Therapeutics company profile. All content is posted anonymously by employees working at Corcept Therapeutics

Corcept Therapeutics Jobs, Employment in United States

Careers. The privacy of your personal information is important to us. Xilio Therapeutics, Inc. and its affiliates will use the information provided by you for recruiting and hiring purposes. Please note that Xilio utilizes the services of third-party vendors to process your information on Xilio's behalf. These third parties provide adequate. A career at Protara is an opportunity to join a vibrant and authentic company with a commitment to people and culture. You will have the opportunity to be a part of a growing team. Anyone that possesses the skills, experience and requirements is invited to apply for the available positions below. Protara Therapeutics, Inc Corcept Therapeutics Incorporated (CORT) Accused of Illicit Sales Practices According to allegations for breaches of fiduciary duty, mismanagement, corporate waste, and violations of the Securities Exchange Act of 1934, in 2012, Corcept Therapeutics Incorporated (CORT) launched its prescription medicine Korlym, which served as Corcept's only.

The other day, the Southern Investigative Reporting Foundation (SIRF) published a report on Corcept Therapeutics (CORT). Corcept Therapeutics is a small pharmaceutical company that markets Korlym (mifepristone) in a rare disease called Cushing's Syndrome, a condition that results from excessive exposure to the cortisol The average salary for Regulatory Affairs and Compliance - Senior Vice President at companies like CORCEPT THERAPEUTICS INC in the United States is $278,890 as of May 27, 2021, but the salary range typically falls between $228,590 and $337,890 I have been working at Corcept Therapeutics. Pros. The salaries are very competitive, even high compared to other pharmaceutical companies. CEO is warm, communicative and the employees like and respect him. Cons. There is a great deal of secrecy and lack of communication with employees from the president Life @ Intellia. At Intellia, we are revolutionizing medicine by harnessing the power of genome editing to develop CRISPR/Cas9 one-time treatments. We bring new hope for people living with severe and life-threatening conditions, such as cancer, genetic disorders, viral infections, inflammatory disorders and many more. View open positions

MENLO PARK, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe. CORCEPT THERAPEUTICS PUBLISHES ABSTRACT IN THE JOURNAL OF THE ENDOCRINE SOCIETY - read this article along with other careers information, tips and advice on BioSpace Corcept Therapeutics Incorporated today announced the publication of an abstract in the April-May supplemental issue of the Journal of the Endocrine Society (JES) InCarda Therapeutics | Transforming Cardiovascular Treatment with Pulmonary Delivery. Transforming. Cardiovascular Treatment. with Pulmonary Delivery. We are a biopharmaceutical company pioneering a novel approach of. treating cardiovascular diseases/conditions by the inhalation route. More about InCarda Corcept Therapeutics is a pharmaceutical company which discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with.

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call Provided by GlobeNewswire Apr 29, 2021 8:05 PM UTC Sponsor Cente About Corcept Therapeutics. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the. Corcept Therapeutics articles and data by Trefis. Stock Return Rankings. Portfolio Wall Street brokerages expect Corcept Therapeutics Incorporated (NASDAQ:CORT) to report $85.83 million in sales for the current quarter, according to Zacks Investment Research.Two analysts have made estimates for Corcept Therapeutics' earnings, with the lowest sales estimate coming in at $85.00 million and the highest estimate coming in at $86.65 million

Jobs with Corcept Therapeutics - BioSpac

Corcept Therapeutics already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in. --Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the. Corcept Therapeutics Inc. is a pharmaceutical company that discovers and develops drugs for the treatment of severe metabolic and psychiatric disorders. The Company's lead product modulates the. Corcept Therapeutics Inc. SEC filings breakout by MarketWatch. View the CORT U.S. Securities and Exchange Commission reporting information News Corcept Therapeutics Inc.CORT. The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings.

Corcept Therapeutics Announces 2017 Financial Results and

Corcept Therapeutics Careers & Jobs - Zippi

Corcept Therapeutics ( CORT) is a Menlo Park, California-based pharmaceutical company that IPO'd in 2004. The company is focused on developing drugs that modulate the effects of cortisol. About Corcept Therapeutics. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing's syndrome Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress. Nasdaq 6/24/2021. Corcept Therapeutics to End Study of Relacorilant Combo for Pancreatic Cancer. MarketWatch 6/22/2021. Are Insiders Buying Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock

Corcept Therapeutics (CORT) Misses Q1 Earnings and Revenue Estimates. 05/06 17:20. MT Newswires. -- Earnings Flash (CORT) CORCEPT THERAPEUTICS INCORPORATED Reports Q1 EPS $0.20, vs. Street Est of $0.19 --Analyst Actions: HC Wainwright Adjusts Corcept Therapeutics' Price Target to $32 From $22, Keeps at Buy MT Newswires 11/27 07:02 ET Corcept Therapeutics Appoints Gillian M. Cannon, PhD, to Board of Director Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2021 Earnings Conference Call May 6, 2021 5:00 PM ET. Company Participants. Atabak Mokari - Chief Financial Officer. Charlie Robb - Chief. Corcept Therapeutics Incorporated (CORT) Q1 2021 Earnings Call Transcript Motley Fool Transcribers 5/7/2021 Postal Service looks to raise first-class stamp to 58 cent Corcept Therapeutics is a pharma company focused on the creation of drugs to treat severe metabolic, oncologic, as well as psychiatric disorders. These drugs do so by affecting the stress hormone.

Corcept Therapeutics: Jobs LinkedI

Corcept Therapeutics Inc., down $1.02 to $21.96. The drug developer halted development of a treatment for end-stage pancreatic cancer. NextGen Healthcare Inc., down 84 cents to $16.64. The health care technology company said CEO Rusty Franz is stepping down, effective immediately. GameStop Corp., up $20.03 to $220.40 Corcept Therapeutics (CORT) Misses Q1 Earnings and Revenue Estimates. by Zacks Equity Research Published on May 06,2021. Corcept (CORT) delivered earnings and revenue surprises of -14.29% and -18. How to buy Corcept Therapeutics Inc stock on Stash. 1. Enter the amount you'd like to invest in Corcept Therapeutics Inc stock, then proceed to checkout. Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive

Corcept Therapeutics - AnnualReports

Corcept Therapeutics Jobs Glassdoo

Pharma Stocks: Why Corcept Therapeutics Stock Is Soaring 24% Today. By William White, InvestorPlace Writer Nov 19, 2020. Corcept Therapeutics (CORT) is leading pharma stocks news on Thursday with. Corcept Therapeutics Incorporated CORT reported earnings of 18 cents per share in first-quarter 2021, missing the Zacks Consensus Estimate of 21 cents. In the year-ago quarter, the company had. Comprehensive health care benefits where 100% of premiums are paid. 401K plan has 100% of fees covered. While the benefits are really great for such a small company, there are still things to improve that would make Corcept even more attractive in a challenging BayArea environment to hire and retain good employees (e.g., stock grants, 401K matching, best-in-class parental/family leave policies

The average salary for Senior Strategic Planning Analyst at companies like CORCEPT THERAPEUTICS INC in the United States is $114,150 as of May 27, 2021, but the salary range typically falls between $101,870 and $129,560 Spark Therapeutics is an equal opportunity employer. We do not discriminate on the basis of race, color, gender, gender identity, sexual orientation, age, religion, national or ethnic origin, disability, protected veteran status or any other basis protected by applicable law Corcept Therapeutics Settles Patent Litigation with Sun Pharmaceutical MENLO PARK, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced that it has entered into. Corcept Therapeutics Inc. said preliminary results from its Phase 3 trial of relacorilant combined with nab-paclitaxel in patients with metastatic pancreatic cancer doesn't justify further study.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol Investors are always looking for stocks that are poised to beat at earnings season and Corcept Therapeutics Incorporated CORT may be one such company. The firm has earnings coming up pretty soon.

Corcept Therapeutics LinkedI

Corcept Therapeutics is based in Menlo Park, Calif., and is a commercial-stage company engaged in the discovery and development of drugs that modulate the effects of the hormone cortisol. The firm stated that Korlym ® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing's syndrome. The company. About Corcept Therapeutics Incorporated. Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. Korlym, a first generation GR-II antagonist, is the company's first FDA-approved medication Corcept Therapeutics General Information Description. Corcept Therapeutics Inc is engaged in the discovery, development, and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol. Careers; Follow us. Corcept Therapeutics Inc., down $1.02 to $21.96. The drug developer halted development of a treatment for end-stage pancreatic cancer. NextGen Healthcare Inc., down 84 cents to $16.64 About the company. Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is dev. eloping mifepristone, a compound that modulates the effects of cortisol by acting as a competitive.

Working at Corcept Therapeutics Glassdoo

Corcept Therapeutics Inc (CORT:NAQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates Corcept is advancing its selective cortisol modulator exicorilant as a treatment for patients with metastatic castration-resistant prostate cancer (CRPC). The company is conducting an open label.

Corcept Therapeutics Reviews Glassdoo

Curated profile of Gregg Alton, Board Member, Corcept Therapeutics including career history, news and intelligence, portfolio companies and investments. Thank you for accessing our content on the Topio Networks Market Intelligence Center Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym About Us Company Careers Plans Login Help Center Simply Wall St News Podcasts Vice President-Corporate Controller. Corcept Therapeutics, Inc. engages in the development of drugs for the treatment of severe psychiatric, neurological, and metabolic disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support

View Rick Bastin's profile on LinkedIn, the world's largest professional community. Rick has 7 jobs listed on their profile. See the complete profile on LinkedIn and discover Rick's connections and jobs at similar companies Corcept Therapeutics uses 18 technology products and services including HTML5, Google Analytics, and jQuery, according to G2 Stack. Corcept Therapeutics is actively using 39 technologies for its website, according to BuiltWith. These include IPhone / Mobile Compatible, Viewport Meta, and SPF James Wilson. Mr. Wilson has served as a director and as Chairman of Corcept Therapeutics's Board since 1999. In addition, since 2005, Mr. Wilson has been the Chairman of the Board of NuGEN Technologies, Inc., a provider of systems for genomic analysis. From 2002 to 2009, he served as the lead independent director of Amylin Pharmaceuticals.

About Corcept Therapeutics Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the. 20 Jobs With the Most Financial Security Corcept Therapeutics (CORT) came out with quarterly earnings of $0.18 per share, missing the Zacks Consensus Estimate of $0.21 per share. This compares to. Corcept Therapeutics, Inc. Corcept Therapeutics, Inc. engages in the development of drugs for the treatment of severe psychiatric, neurological, and metabolic disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support MENLO PARK, Calif. (Nov. 23, 2020) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Gillian M. Cannon, PhD, has joined the company's Board of Directors Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic.

Corcept Therapeutics: The Company That Perfectly Explains

CORT: Corcept Therapeutics Incorporated - Interactive Chart Chart. Get the latest Interactive Chart for Corcept Therapeutics Incorporated from Zacks Investment Researc Item 8.01. Other Events. On February 3, 2021, Corcept Therapeutics Incorporated (the Company) announced that it has received a Paragraph IV Notice Letter advising that Hikma Pharmaceuticals. Corcept Therapeutics To Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call July 22, 2021 Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edem MENLO PARK, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate. Curated profile of Kimberly Park, Board Member, Corcept Therapeutics including career history, news and intelligence, portfolio companies and investments. Thank you for accessing our content on the Topio Networks Market Intelligence Center